On August 20, 2026, a new clinical trial update was recorded for semaglutide depot, an approved compound. The study, registered as NCT07563699, is titled "Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus." It is listed as a combined Phase 1/Phase 2 trial. The trial's current status is recruiting, meaning it is actively seeking participants as of the listed date.
According to the registration, the study aims to examine safety, tolerability, and efficacy of the semaglutide depot formulation in people with type 2 diabetes mellitus. No results have been posted for this trial at this time. The trial's phase classification indicates it is in an early stage of clinical evaluation, combining Phase 1 and Phase 2 objectives.
This update reflects only the trial's registration status and does not include outcome data. Readers should not interpret an active recruiting status as an indication of eventual safety or efficacy findings. Further updates will depend on future postings to the trial record.
For more background on this compound, see the linked compound overview.